Signorelli Francesco, Gory Benjamin, Pelissou-Guyotat Isabelle, Guyotat Jacques, Riva Roberto, Dailler Frédéric, Turjman Francis
Department of Neurosurgery, Hospices Civils de Lyon, Université Claude Bernard, "Pierre Wertheimer", 59, Boulevard Pinel, 69500, Lyon, France,
Neuroradiology. 2014 Sep;56(9):763-9. doi: 10.1007/s00234-014-1395-2. Epub 2014 Jun 28.
The impact of targeted embolization of ruptured cerebral arteriovenous malformation (AVM)-associated arterial aneurysms in the acute phase of bleeding is not well known. The objective of our study was to analyze the safety and efficacy of this treatment strategy with special emphasis on its protective effect against rebleeding.
From a prospective database, all patients presenting between December 2005 and March 2012 with a ruptured cerebral AVM associated with arterial aneurysms contiguous to the hemorrhage were selected. Hemorrhagic stroke severity and clinical outcome were measured using, respectively, Glasgow Coma Scale (GCS) and modified Rankin Scale (mRS) scores.
Twenty-five patients with ruptured cerebral AVMs associated with 31 arterial aneurysms contiguous with the hemorrhage were included. In the first group of 17 patients, the mean time to treatment was 30.1 h, while in the second group with 1 patient in poor initial clinical conditions and 7 admitted 7 to 28 days after bleeding, it was 17 days. All arterial aneurysms were totally occluded. Four patients presented rebleeding before treatment (mean interval 9.6 days) and four had rebleeding after treatment (mean interval 8.25 months). At a mean follow-up of 56 months, 21 patients were alive (19 mRS ≤ 2, 2 mRS > 2). Three patients died 2 days, 9 days, and 2 months after bleeding and another died of rebleeding of her residual AVM 19 months after treatment. Treatment-related morbidity and mortality were, respectively, 4 and 0%.
Selective embolization of arterial aneurysms associated with ruptured AVMs is a safe procedure and could lower the immediate risk of rebleeding.
在脑出血急性期,对破裂的脑动静脉畸形(AVM)相关动脉性动脉瘤进行靶向栓塞的影响尚不清楚。我们研究的目的是分析这种治疗策略的安全性和有效性,特别强调其对再出血的预防作用。
从一个前瞻性数据库中,选取2005年12月至2012年3月期间出现与出血部位相邻的动脉性动脉瘤相关的破裂脑AVM的所有患者。分别使用格拉斯哥昏迷量表(GCS)和改良Rankin量表(mRS)评分来衡量出血性中风的严重程度和临床结局。
纳入了25例与31个与出血部位相邻的动脉性动脉瘤相关的破裂脑AVM患者。第一组17例患者的平均治疗时间为30.1小时,而第二组有1例初始临床状况较差且7例在出血后7至28天入院的患者,平均治疗时间为17天。所有动脉性动脉瘤均完全闭塞。4例患者在治疗前出现再出血(平均间隔9.6天),4例在治疗后出现再出血(平均间隔8.25个月)。平均随访56个月时,21例患者存活(19例mRS≤2,2例mRS>2)。3例患者在出血后2天、9天和2个月死亡,另1例在治疗后19个月死于残留AVM的再出血。治疗相关的发病率和死亡率分别为4%和0%。
对与破裂AVM相关的动脉性动脉瘤进行选择性栓塞是一种安全的手术,可降低立即再出血的风险。